ALK and non-small cell lung carcinoma: As shown in the tornado diagram of ALK-positive advanced NSCLC patients in Figure 2, parameters that most influenced the incremental cost-effectiveness ratio were the cost of brigatinib, cost of pemetrexed, and utility of second-line treatment.